ClinicalTrials.gg
CompletedNCT02163733Updated Jan 22, 2024Results posted

Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer

A Phase 1 interventional study of AZD9291 tablets and Pharmacokinetic sampling - AZD9291 in Advanced Non Small Cell Lung Cancer and Advanced (Inoperable) Non Small Cell Lung Cancer, sponsored by AstraZeneca. Completed at 13 sites in 4 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-01-22.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
60th of 90
38 · median 51
Started
2014
with 9 others
Phase 1
18 of 90
1 open now
Registered
4th of 90
by date
Lead sponsor
29 of 90
AstraZeneca

Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 60th largest by enrollment, is one of 10 that started in 2014, is one of 18 in phase 1, and was the 4th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a 2-part study in patients with epidermal growth factor receptor mutation positive (EGFRm+) non-small cell lung cancer (NSCLC) whose disease has progressed on treatment with an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI): Part A will determine the effect of food on the pharmacokinetics (PK) of AZD9291; Part B will allow patients further access to AZD9291 and will provide for additional safety data collection.

Part A is a randomised, open-label, 2 treatment period crossover study in which patients will each receive a single oral dose of AZD9291 (1 x 80 mg tablet) at breakfast time (approximately 0800) in each of 2 treatment periods (once immediately following a high fat meal [fed], and once in the fasted state [fasted]), with a washout period of 9 days between doses.

Approximately 38 patients are planned to be enrolled and dosed; at least 30 evaluable patients will be required to complete Part A (ie, the last PK sample in Treatment Period 2 [TP 2] has been collected). Additional patients may be enrolled to allow for at least 30 evaluable patients

03

Conditions studied

  • Advanced Non Small Cell Lung Cancer
  • Advanced (Inoperable) Non Small Cell Lung Cancer

Keywords

  • oncology, cancer, non small cell lung cancer, anticancer drug, pharmacokinetics, AZD9291, EGFR sensitivity mutation, food effect
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

For inclusion in the study patients should fulfil the following criteria:

  1. Male or female, aged at least 18 years.
  2. Able to eat a high-fat meal within a 30-minute period, as provided by the study site.
  3. Histologically or, where appropriate, confirmed NSCLC.
  4. Radiological documentation of disease progression while on a previous continuous treatment with an EGFR TKI. In addition, other may have been given. All patients must have documented radiological progression on the last treatment administered prior to enrolling in the study.
  5. Confirmation that the tumour harbours an EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q).
  6. performance status 0-1 with no deterioration over the previous 2 weeks.
  7. Patients must have a of ≥12 weeks, as estimated at the time of screening.
  8. Females should be using adequate measures and must have a negative pregnancy test prior to start of dosing if of , or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening: defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments; Women under 50 years old would be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone and follicle stimulating hormone levels in the post-menopausal range for the institution; Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, but not tubal ligation.
  9. Male patients should be willing to use barrier contraception, ie, condoms, until 6 months after last study drug is taken.

Patients should not enter the study if any of the following exclusion criteria are fulfilled:

  1. Participation in another clinical study with an IP during the last 14 days (or a longer period depending on the defined characteristics of the agents used).
  2. Treatment with any of the following: Treatment with an EGFR TKI w/in 8 days or approximately 5x half-life, whichever is the longer, of the first dose of study treatment; Any cytotoxic chemotherapy, agents or other anticancer drugs w/in 14 days of the first dose of study treatment; Major surgery (excluding placement of vascular access) within 4 weeks of the first dose; Radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of study treatment, with the exception of patients receiving radiation to more than 30% of the bone marrow or with a wide field of radiation which must be completed within 4 weeks of the first dose of study treatment; Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inhibitors of CYP2C8 and of (at least 1 week prior) and potent inducers of CYP3A4 (at least 3 week prior). All patients must try to avoid concomitant use of any medications, herbal supplements and/or ingestion of foods with known inducer/inhibitory effects on CYP3A4, CYP2C8, and/ or CYP1A2.
  3. Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade, or other products containing grapefruit or Seville oranges within 7 days of the first administration of the IP until the end of Part A.
  4. Any unresolved toxicities from prior therapy greater than Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum therapy related neuropathy.
  5. Patients unable to fast for up to 14 hours.
  6. Spinal cord compression or unless asymptomatic, stable and not requiring for at least 4 weeks prior to start of study treatment.
  7. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses, which in the Investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardise compliance with the protocol, or active infection including , and . Screening for chronic conditions is not required.
  8. Patients with type I diabetes.
  9. Patients unable to swallow orally administered medication or patients with gastrointestinal disorders or significant gastrointestinal resection likely to interfere with the absorption of AZD9291.
  10. Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
  11. Women who are breastfeeding.
  12. Patients with a known to AZD9291
  13. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values: (ANC) \<1.5 x 109/L; count \<100 x 109/L; \<90 g/L; >2.5 x the institutional if no demonstrable liver or >5 x institutional ULN in the presence of liver metastases; AST >2.5 x institutional ULN if no demonstrable liver metastases or >5 x institutional ULN in the presence of liver metastases; Total >1.5 x institutional ULN if no liver metastases or >3 x institutional ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia) or liver metastases; Creatinine >1.5 x institutional ULN concurrent with \<50 mL/min (measured or calculated by Cockcroft-Gault formula); confirmation of creatinine clearance is only required when creatinine is >1.5 x institutional ULN.
  14. Any of the following cardiac criteria: Mean resting interval corrected for heart rate using Fridericia's correction factor (QTcF) >470 msec obtained from 3 ECGs; Any abnormalities in rhythm, conduction or morphology of resting eg, complete left bundle branch block, third degree heart block, second degree heart block, PR interval >250 msec; Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval.
  15. For optional genetic research: Previous allogenic bone marrow transplant or non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Other
    Fasted

    AZD9291 tablets following a period of fasting

    Drug: AZD9291 tablets · Procedure: Pharmacokinetic sampling - AZD9291 · Other: Dietary Fasted · Procedure: Pharmacokinetic sampling - AZ5140 and AZ7550

  • Other
    High-fat meal

    AZD9291 tablets following a high-fat meal.

    Drug: AZD9291 tablets · Procedure: Pharmacokinetic sampling - AZD9291 · Other: Dietary High Fat · Procedure: Pharmacokinetic sampling - AZ5140 and AZ7550

Interventions

  • AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.

  • ProcedurePharmacokinetic sampling - AZD9291

    Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.

  • OtherDietary Fasted

    Fasted from 10 hours prior to dosing with 80mg AZD9291 tablet and 4 hours after dosing

  • OtherDietary High Fat

    Allocated breakfast prior to dosing with 80mg AZD9291 tablet

  • ProcedurePharmacokinetic sampling - AZ5140 and AZ7550

    Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.

06

What researchers measure

Primary outcomes

  1. AUC(0-72) of AZD9291

    Pharmacokinetics of AZD9291 by assessment of area under the plasma concentration time curve from zero to 72 hours.

    Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 hours post AZD9291 dose in Part A.

  2. Cmax of AZD9291

    Pharmacokinetics of AZD9291 by assessment of maximum plasma AZD9291 concentration.

    Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.

Secondary outcomes

  1. AUC of AZD9291

    Area under the plasma concentration curve from zero extrapolated to infinity.

    Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.

  2. AUC(0-t) of AZD9291

    Area under the plasma concentration curve from time zero to last quantifiable dose.

    Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.

  3. AUC(0-120) of AZD9291

    Pharmacokinetics of AZD9291 by assessment of area under the plasma concentration time curve from zero to 120 hours.

    Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 120 hours post AZD9291 dose in Part A.

  4. Tmax of AZD9291

    Pharmacokinetics of AZD9291 by assessment of time to Cmax.

    Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.

  5. t1/2 of AZD9291

    Pharmacokinetics of AZD9291 by assessment of the terminal half-life.

    Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.

  6. CL/F of AZD9291

    Rate and extent of absorption of AZD9291 by assessment of apparent clearance following oral administration.

    Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.

  7. Vz/F of AZD9291

    Rate and extent of absorption of AZD9291 by assessment of the apprarent volume of distribution.

    Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.

  8. AUC(0-72) of AZ5104 and AZ7550

    Pharmacokinetics of AZ5104 and AZ7550 (metabolites to AZD9291) by assessment of area under the plasma concentration time curve from zero to 72 hours.

    Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 hours post AZD9291 dose in Part A.

  9. Cmax of AZ5104 and AZ7550

    Pharmacokinetics of AZ5104 and AZ7550 (metabolites to AZD9291) by assessment of maximum plasma concentration.

    Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.

  10. AUC(0-t) of AZ5104 and AZ7550

    Area under the plasma concentration curve from time zero to last quantifiable dose for AZ5104 and AZ7550 (metabolites to AZD9291).

    Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.

  11. AUC(0-120) of AZ5104 and AZ7550

    Pharmacokinetics of AZ5104 and AZ7550 (metabolites to AZD9291) by assessment of area under the plasma concentration time curve from zero to 120 hours.

    Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 120 hours post AZD9291 dose in Part A.

  12. Tmax of AZ5104 and AZ7550

    Pharmacokinetics of AZ5104 and AZ7550 (metabolites to AZD9291) by assessment of time to Cmax.

    Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.

  13. t1/2 of AZ5104 and AZ7550

    Pharmacokinetics of AZ5104 and AZ7550 (metabolites to AZD9291) by assessment of the terminal half-life.

    Time frame: Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.

07

Results

Posted Apr 5, 2016
Limitations and caveats
At end of Part B, the CAP allowed patients to continue receiving AZD9291 if still deriving clinical benefit. No clinical data was databased during the CAP; thus AE data is presented to end of Part B only.

Participant flow

First subject enrolled: 14 November 2014; Last Subject Last Visit for Part A: 23 March 2015 and Part B: 22 March 2016. The study was performed at 12 sites across Asia and Western Europe. Part A determined effect of food on PK of AZD9291; Part B allowed subjects further access to AZD9291 and provided additional safety data.

Part A: Day 1-9 (1st Intervention)
Participant flow — Part A: Day 1-9 (1st Intervention)
MilestoneFed/FastedFasted/FedAZD9291 Alone (Part B)
Started18200
Completed18200
Not completed000
Part A: Day 10-15 (2nd Intervention)
Participant flow — Part A: Day 10-15 (2nd Intervention)
MilestoneFed/FastedFasted/FedAZD9291 Alone (Part B)
Started18200
Completed18200
Not completed000
Part B: Day 15 to End Part B (AZD9291)
Participant flow — Part B: Day 15 to End Part B (AZD9291)
MilestoneFed/FastedFasted/FedAZD9291 Alone (Part B)
Started0038
Completed0014
Not completed0024
Withdrew: Death005
Withdrew: Disease progression0019

Outcome measures

PrimaryAUC(0-72) of AZD9291

Pharmacokinetics of AZD9291 by assessment of area under the plasma concentration time curve from zero to 72 hours.

Time frame:
Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 hours post AZD9291 dose in Part A.
Reported as:
Geometric mean · nM*h
AUC(0-72) of AZD9291
nM*hFed (High-fat Meal)Fasted
AUC(0-72) of AZD92917403 (3170 to 15600)7345 (3400 to 14700)
Statistical analysis
  • Fed (High-fat Meal) vs Fasted · Geometric mean ratio: 106.05 · 90% CI 94.82 to 118.60Fed / Fasted ratio. Linear mixed-effects model with sequence, period, and treatment as fixed effects and subject nested within sequence as a random effect. Least squares geometric mean ratio (LSGMR) Fed = 7847, Fasted = 7399.
PrimaryCmax of AZD9291

Pharmacokinetics of AZD9291 by assessment of maximum plasma AZD9291 concentration.

Time frame:
Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.
Reported as:
Geometric mean · nM
Cmax of AZD9291
nMFed (High-fat Meal)Fasted
Cmax of AZD9291199.6 (80.8 to 446)218.0 (95.2 to 381)
Statistical analysis
  • Fed (High-fat Meal) vs Fasted · Geometric mean ratio: 92.75 · 90% CI 81.40 to 105.68Fed / Fasted ratio. Linear mixed-effects model with sequence, period, and treatment as fixed effects and subject nested within sequence as a random effect. LSGMR Fed = 208.0, Fasted = 224.3.
SecondaryAUC of AZD9291

Area under the plasma concentration curve from zero extrapolated to infinity.

Time frame:
Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.
Reported as:
Geometric mean · nM*h
AUC of AZD9291
nM*hFed (High-fat Meal)Fasted
AUC of AZD929111640 (5460 to 24100)12530 (6050 to 25500)
SecondaryAUC(0-t) of AZD9291

Area under the plasma concentration curve from time zero to last quantifiable dose.

Time frame:
Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.
Reported as:
Geometric mean · nM*h
AUC(0-t) of AZD9291
nM*hFed (High-fat Meal)Fasted
AUC(0-t) of AZD929110820 (4860 to 21800)10630 (5300 to 22600)
SecondaryAUC(0-120) of AZD9291

Pharmacokinetics of AZD9291 by assessment of area under the plasma concentration time curve from zero to 120 hours.

Time frame:
Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 120 hours post AZD9291 dose in Part A.
Reported as:
Geometric mean · nM*h
AUC(0-120) of AZD9291
nM*hFed (High-fat Meal)Fasted
AUC(0-120) of AZD92919549 (4360 to 18800)9308 (4480 to 18900)
SecondaryTmax of AZD9291

Pharmacokinetics of AZD9291 by assessment of time to Cmax.

Time frame:
Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.
Reported as:
Median · h
Tmax of AZD9291
hFed (High-fat Meal)Fasted
Tmax of AZD92917.97 (3.02 to 24.13)6.08 (3.00 to 10.07)
Secondaryt1/2 of AZD9291

Pharmacokinetics of AZD9291 by assessment of the terminal half-life.

Time frame:
Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.
Reported as:
Geometric mean · h
t1/2 of AZD9291
hFed (High-fat Meal)Fasted
t1/2 of AZD929152.82 (32.1 to 84.4)54.64 (31.2 to 84.0)
SecondaryCL/F of AZD9291

Rate and extent of absorption of AZD9291 by assessment of apparent clearance following oral administration.

Time frame:
Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.
Reported as:
Geometric mean · L/h
CL/F of AZD9291
L/hFed (High-fat Meal)Fasted
CL/F of AZD929113.75 (6.65 to 29.3)12.78 (6.28 to 26.5)
SecondaryVz/F of AZD9291

Rate and extent of absorption of AZD9291 by assessment of the apprarent volume of distribution.

Time frame:
Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.
Reported as:
Geometric mean · L
Vz/F of AZD9291
LFed (High-fat Meal)Fasted
Vz/F of AZD92911024 (470 to 2580)1019 (432 to 2200)
SecondaryAUC(0-72) of AZ5104 and AZ7550

Pharmacokinetics of AZ5104 and AZ7550 (metabolites to AZD9291) by assessment of area under the plasma concentration time curve from zero to 72 hours.

Time frame:
Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48 and 72 hours post AZD9291 dose in Part A.
Reported as:
Geometric mean · nM*h
AUC(0-72) of AZ5104 and AZ7550
nM*hFed (High-fat Meal)Fasted
AZ5104497.6 (138 to 1360)613.2 (270 to 1450)
AZ7550235.0 (82.7 to 1140)266.4 (112 to 590)
Statistical analysis
  • Fed (High-fat Meal) vs Fasted · Geometric mean ratio: 81.15 · 90% CI 57.86 to 113.83Fed / Fasted ratio. No pre-specified margins for equivalence test for metabolites, but analysed for consistency with AZD9291 analysis. Linear mixed-effects model with treatment as fixed effect. LSGMR Fed = 497.6, Fasted = 613.2.
  • Fed (High-fat Meal) vs Fasted · Geometric mean ratio: 88.21 · 90% CI 65.21 to 119.32Fed / Fasted ratio. No pre-specified margins for equivalence test for metabolites, but analysed for consistency with AZD9291 analysis. Linear mixed-effects model with treatment as fixed effect. LSGMR Fed = 235.0, Fasted = 266.4.
SecondaryCmax of AZ5104 and AZ7550

Pharmacokinetics of AZ5104 and AZ7550 (metabolites to AZD9291) by assessment of maximum plasma concentration.

Time frame:
Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.
Reported as:
Geometric mean · nM
Cmax of AZ5104 and AZ7550
nMFed (High-fat Meal)Fasted
AZ51049.163 (2.94 to 24.7)11.95 (4.95 to 28.6)
AZ75504.236 (1.76 to 19.7)5.109 (1.78 to 11.3)
Statistical analysis
  • Fed (High-fat Meal) vs Fasted · Geometric mean ratio: 76.68 · 90% CI 55.31 to 106.32Fed / Fasted ratio. No pre-specified margins for equivalence test for metabolites, but analysed for consistency with AZD9291 analysis. Linear mixed-effects model with treatment as fixed effect. LSGMR Fed = 9.163, Fasted = 11.95.
  • Fed (High-fat Meal) vs Fasted · Geometric mean ratio: 82.92 · 90% CI 60.99 to 112.74Fed / Fasted ratio. No pre-specified margins for equivalence test for metabolites, but analysed for consistency with AZD9291 analysis. Linear mixed-effects model with treatment as fixed effect. LSGMR Fed = 4.236, Fasted = 5.109.
SecondaryAUC(0-t) of AZ5104 and AZ7550

Area under the plasma concentration curve from time zero to last quantifiable dose for AZ5104 and AZ7550 (metabolites to AZD9291).

Time frame:
Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.
Reported as:
Geometric mean · nM*h
AUC(0-t) of AZ5104 and AZ7550
nM*hFed (High-fat Meal)Fasted
AZ51041033 (266 to 2590)1132 (535 to 2640)
AZ7550584.5 (178 to 2530)591.9 (270 to 1090)
SecondaryAUC(0-120) of AZ5104 and AZ7550

Pharmacokinetics of AZ5104 and AZ7550 (metabolites to AZD9291) by assessment of area under the plasma concentration time curve from zero to 120 hours.

Time frame:
Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 and 120 hours post AZD9291 dose in Part A.
Reported as:
Geometric mean · nM*h
AUC(0-120) of AZ5104 and AZ7550
nM*hFed (High-fat Meal)Fasted
AZ5104744.4 (206 to 2050)875.7 (408 to 1940)
AZ7550373.4 (127 to 1820)411.4 (178 to 850)
SecondaryTmax of AZ5104 and AZ7550

Pharmacokinetics of AZ5104 and AZ7550 (metabolites to AZD9291) by assessment of time to Cmax.

Time frame:
Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.
Reported as:
Median · h
Tmax of AZ5104 and AZ7550
hFed (High-fat Meal)Fasted
AZ510424.17 (8.08 to 72.75)8.03 (4.00 to 49.03)
AZ755024.60 (8.08 to 120.58)10.00 (6.00 to 73.53)
Secondaryt1/2 of AZ5104 and AZ7550

Pharmacokinetics of AZ5104 and AZ7550 (metabolites to AZD9291) by assessment of the terminal half-life.

Time frame:
Blood samples collected on Day 1 and Day 10 at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, and 216 hours post AZD9291 dose in Part A.
Reported as:
Geometric mean · h
t1/2 of AZ5104 and AZ7550
hFed (High-fat Meal)Fasted
AZ510464.74 (45.9 to 113)62.89 (43.3 to 96.2)
AZ755085.26 (52.2 to 142)91.54 (58.2 to 204)

Adverse events

Collected over Approximately 2 weeks for Part A; up to approximately 15 months for Part B and approximately 15.5 months for Overall (Parts A and B combined).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Overall Safety Population2/38 (5.3%)8/38 (21.1%)38/38 (100%)
Part A Safety Population0/38 (0%)1/38 (2.6%)20/38 (52.6%)
Part B Safety Population2/38 (5.3%)7/38 (18.4%)37/38 (97.4%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventOverall Safety PopulationPart A Safety PopulationPart B Safety Population
PNEUMONIAInfections and infestations2/380/382/38
ATRIAL FLUTTERCardiac disorders1/381/380/38
LOWER RESPIRATORY TRACT INFECTION BACTERIALInfections and infestations1/380/381/38
NEUTROPENIC SEPSISInfections and infestations1/380/381/38
PNEUMONIA PNEUMOCOCCALInfections and infestations1/380/381/38
SEPSISInfections and infestations1/380/381/38
HYPONATRAEMIAMetabolism and nutrition disorders1/380/381/38
BACK PAINMusculoskeletal and connective tissue disorders1/380/381/38
INTERVERTEBRAL DISC COMPRESSIONMusculoskeletal and connective tissue disorders1/380/381/38
CANCER PAINNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/380/381/38
Most frequent other events
Showing 10 of 69
Most frequent other events
EventOverall Safety PopulationPart A Safety PopulationPart B Safety Population
DIARRHOEAGastrointestinal disorders21/384/3819/38
DRY SKINSkin and subcutaneous tissue disorders12/380/3812/38
NAUSEAGastrointestinal disorders10/384/388/38
PARONYCHIAInfections and infestations10/381/389/38
DECREASED APPETITEMetabolism and nutrition disorders10/381/389/38
FATIGUEGeneral disorders9/381/388/38
BACK PAINMusculoskeletal and connective tissue disorders8/381/387/38
ANAEMIABlood and lymphatic system disorders6/383/383/38
VOMITINGGastrointestinal disorders6/384/385/38
MUSCULOSKELETAL CHEST PAINMusculoskeletal and connective tissue disorders6/381/386/38

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Fed/FastedFasted/FedTotal
Mean64.1 ± 11.9861.4 ± 11.0062.7 ± 11.40
Sex: Female, Male
Sex: Female, Male(Participants)Fed/FastedFasted/FedTotal
Female161026
Male21012
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Fed/FastedFasted/FedTotal
American Indian or Alaska Native000
Asian426
Native Hawaiian or Other Pacific Islander000
Black or African American000
White141731
More than one race000
Unknown or Not Reported011
08

Study locations

13 sites
  • Research Site
    Dijon cedex, 21079, France
  • Research Site
    Lyon Cedex 08, 69373, France
  • Research Site
    Saint Herblain, 44805, France
  • Research Site
    Seoul, 03722, Korea, Republic of
  • Research Site
    Seoul, 05505, Korea, Republic of
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Madrid, 28050, Spain
  • Research Site
    Sevilla, 41013, Spain
  • Research Site
    London, SE1 9RT, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom
  • Research Site
    Newcastle upon Tyne, NE7 7DN, United Kingdom
  • Research Site
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Publications

  • Vishwanathan K, Dickinson PA, Bui K, Cassier PA, Greystoke A, Lisbon E, Moreno V, So K, Thomas K, Weilert D, Yap TA, Plummer R. The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers. J Clin Pharmacol. 2018 Apr;58(4):474-484. doi: 10.1002/jcph.1035. Epub 2017 Nov 26. PubMed 29178442 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Mar 2015, 4 months.

Results were first posted in Apr 2016, 1 year after primary completion.

Of 473 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 4 months is below that.

Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2014
First posted
Jun 16, 2014
StartActual
Nov 14, 2014
Primary completionActual
Mar 24, 2015
CompletionActual
Jan 24, 2023
Results first posted
Apr 5, 2016
Last update
Jan 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02163733
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 16, 2014
Start date
Nov 14, 2014
Primary completion
Mar 24, 2015
Completion
Jan 24, 2023
Results posted
Apr 5, 2016
Last update
Jan 22, 2024

Study contacts

Serban Ghiorghiu, MSD
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion